Brain parenchymal angiomatoid fibrous histiocytoma and spinal myxoid mesenchymal tumor with FET: CREB fusion, a spectrum of the same tumor type
- 22 June 2022
- journal article
- review article
- Published by Wiley in Neuropathology
- Vol. 42 (4) , 257-268
Abstract
Angiomatoid fibrous histiocytomas (AFH) is a rare soft tissue tumor of intermediate malignant potential, and its histology is diverse. It can occur in several organs including intracranial and soft tissues. Here, we report two cases of brain parenchymal classic AFH and spinal extramedullary myxoid mesenchymal tumor with clinicopathological and molecular investigations by next‐generation sequencing and a comprehensive review. The current brain parenchymal AFH occurred in a 79‐year‐old woman, and the spinal myxoid mesenchymal tumor arose in the thoracic spine of a 28‐year‐old woman; both harbored FET:CREB fusion. The current brain parenchymal AFH has not recurred for 15‐months follow‐up period, but the spinal myxoid mesenchymal tumor recurred three times and metastasized to T8 spine level for 30‐months follow‐up period. We reviewed 40 reported cases of central nervous system (CNS) AFHs/myxoid mesenchymal tumors including our two cases to identify clinicopathological features and biological behaviors. They occur with a slight female predominance (M:F = 1:1.7) in children and young adults (median age: 17 years; range: 4–79 years old). Approximately 80% of CNS AFHs were younger than 30 year. Most of them were dura‐based and were not just intracranial tumors as they occurred anywhere in the CNS including spinal dura. EWSR1 rearrangement was the most common driver (98%), including FET:CREB (33%), EWSR1:ATF1 (30%), and EWSR1:CREM (27%) fusions, but FUS:CREM fusion (2%) was also present. During the follow‐up period (median: 27 months), 43% (17/40) of CNS AFHs recurred between two months and 11 years, and multiple recurrences were also observed. One case showed metastases to the lymph nodes and vertebrae, and among 11 cases that resulted in death, four cases provided available clinical data. Because these tumors are identical to soft tissue AFH or primary pulmonary myxoid sarcoma with an FET:CREB fusion in morphological and immunohistochemical spectra, the authors propose incorporating the two tumor terms into one.Keywords
Funding Information
- Institute for Information and Communications Technology Promotion (2019‐0567)
This publication has 30 references indexed in Scilit:
- EWSR1 Fusions With CREB Family Transcription Factors Define a Novel Myxoid Mesenchymal Tumor With Predilection for Intracranial LocationAmerican Journal of Surgical Pathology, 2017
- DNA methylation heterogeneity defines a disease spectrum in Ewing sarcomaNature Medicine, 2017
- Angiomatoid fibrous histiocytoma: a series of seven cases including genetically confirmed aggressive cases and a literature reviewBMC Musculoskeletal Disorders, 2017
- Primary intracranial angiomatoid fibrous histiocytoma presenting with anaemia and migraine-like headaches and aura as early clinical featuresCephalalgia, 2015
- Angiomatoid fibrous histiocytoma: clinicopathological and molecular characterisation with emphasis on variant histomorphologyJournal of Clinical Pathology, 2013
- Primary pulmonary myxoid sarcoma with EWSR1‐CREB1 fusion, resembling extraskeletal myxoid chondrosarcoma: Case report with a review of LiteraturePathology International, 2012
- Tumors With EWSR1-CREB1 and EWSR1-ATF1 FusionsAmerican Journal of Surgical Pathology, 2012
- Intracranial angiomatoid fibrous histiocytoma presenting as recurrent multifocal intraparenchymal hemorrhageJournal of Neurosurgery, 2010
- Primary Intracerebral Angiomatoid Fibrous HistiocytomaAmerican Journal of Surgical Pathology, 2008
- The Myxoid/Round Cell Liposarcoma Fusion Oncogene FUS-DDIT3 and the Normal DDIT3 Induce a Liposarcoma Phenotype in Transfected Human Fibrosarcoma CellsThe American Journal of Pathology, 2006